MedPath

Clonazepam

CLONAZEPAM TABLETS, USP

Approved
Approval ID

dd29b11f-797a-4d05-a564-8d73d1ea93e0

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 10, 2010

Manufacturers
FDA

TYA Pharmaceuticals

DUNS: 938389038

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Clonazepam

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code64725-3004
Application NumberANDA074869
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clonazepam
Product Specifications
Route of AdministrationORAL
Effective DateSeptember 15, 2011
FDA Product Classification

INGREDIENTS (6)

LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
CLONAZEPAMActive
Quantity: 1 mg in 1 1
Code: 5PE9FDE8GB
Classification: ACTIB
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT

Clonazepam

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code64725-3005
Application NumberANDA074869
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clonazepam
Product Specifications
Route of AdministrationORAL
Effective DateSeptember 15, 2011
FDA Product Classification

INGREDIENTS (5)

STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CLONAZEPAMActive
Quantity: 2 mg in 1 1
Code: 5PE9FDE8GB
Classification: ACTIB
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Clonazepam - FDA Drug Approval Details